Literature DB >> 10484475

Dexfenfluramine increases pulmonary artery smooth muscle intracellular Ca2+, independent of membrane potential.

H L Reeve1, S L Archer, M Soper, E K Weir.   

Abstract

The anorexic agent dexfenfluramine causes the development of primary pulmonary hypertension in susceptible patients by an unknown mechanism that may include changes in K+-channel activity and intracellular Ca2+ concentration ([Ca2+]i). We investigated the dose-dependent effects of dexfenfluramine on [Ca2+]i, K+ current, and membrane potential in freshly dispersed rat pulmonary artery smooth muscle cells. Dexfenfluramine caused a dose-dependent (1-1,000 microM) increase in [Ca2+]i, even at concentrations lower than those necessary to inhibit K+ currents (10 microM) and cause membrane depolarization (100 microM). The [Ca2+]i response to 1 and 10 microM dexfenfluramine was completely abolished by pretreatment of the cells with 0.1 microM thapsigargin, whereas the response to 100 microM dexfenfluramine was reduced. CoCl2 (1 mM), removal of extracellular Ca2+, and pretreatment with caffeine (1 mM) reduced but did not abolish the response to 100 microM dexfenfluramine. We conclude that dexfenfluramine increases [Ca2+]i in rat pulmonary artery smooth muscle cells by both release of Ca2+ from the sarcoplasmic reticulum and influx of extracellular Ca2+.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10484475     DOI: 10.1152/ajplung.1999.277.3.L662

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  4 in total

Review 1.  Transglutaminase 2-mediated serotonylation in pulmonary hypertension.

Authors:  K C Penumatsa; B L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-12-27       Impact factor: 5.464

Review 2.  Pulmonary hypertension: therapeutic targets within the serotonin system.

Authors:  Y Dempsie; M R MacLean
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

3.  The impact of extracellular and intracellular Ca2+ on ethanol-induced smooth muscle contraction.

Authors:  Naciye Yaktubay Döndaş; Mahir Kaplan; Derya Kaya; Ergin Singirik
Journal:  Acta Pharmacol Sin       Date:  2009-09-14       Impact factor: 6.150

4.  Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension.

Authors:  Yvonne Dempsie; Neil A MacRitchie; Kevin White; Ian Morecroft; Audrey F Wright; Margaret Nilsen; Lynn Loughlin; Kirsty M Mair; Margaret R MacLean
Journal:  Cardiovasc Res       Date:  2013-03-20       Impact factor: 10.787

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.